English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduWhile chemotherapy has advanced in personalization, personalized radiation therapy for cancer remains underdeveloped. A new project will use AI, in particular, deep reinforcement learning, to analyze multimodal data, and enhance cancer characterization and treatment to ultimately improve patient outcomes. Using personal health data, genetic information about the tumor, and patient treatment and follow-up data, digital twins will simulate diagnoses and treatment options to help physicians choose the most effective treatments and monitor responses over time.
Tag: Chemotherapy
MD Anderson Research Highlights for July 24, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Travel Distance Does Not Affect Overall Survival in Patients with Appendiceal Adenocarcinoma Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Abstract Introduction Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a potentially curative approach for appendiceal cancer (AC) with peritoneal dissemination and is most often employed at tertiary referral centers. Regionalization may provide geographic barriers to care for vulnerable patients.…
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
Intensity Therapeutics, Inc. , a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors directly and increase immune system recognition of cancers, announces that the first U.S. patient has been dosed in the Company’s Phase 3 study to treat metastatic sarcoma (NCT06263231).
New Treatment for Uterine Cancer Receives FDA Approval
The U.S. Food & Drug Administration has approved use of a new treatment option for patients with advanced or recurring uterine cancer. The news comes after completion of the first Phase III trial to statistically evaluate an anti-PD1 immunotherapy, called…
Chemotherapy disrupts gut microbiome in patients with breast cancer
“For the first time ever, our Intelligut Study found that the gut microbiome has been implicated in cognitive side effects of chemotherapy in humans,” said senior author Leah Pyter, associate professor of psychiatry and neuroscience with The Ohio State University Wexner Medical Center and College of Medicine.
MD Anderson Research Highlights for June 5, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Emma Guttman-Yassky, MD, PhD, Receives High Honor at European Academy of Allergy and Clinical Immunology
The Paul Ehrlich Award for Experimental Research recognizes scientists who have revolutionized the understanding of allergic diseases and immunological mechanisms.
Trilaciclib use for prevention of hematological adverse events in chemotherapy: A meta-analysis of real-world studies and clinical trials
Background: Trilaciclib, a cyclin-dependent kinase (CDK)-4 and -6 inhibitor, is the only FDA-approved agent that preemptively protects hematopoietic stem cells from chemotherapy-induced myelosuppression (CIM) without compromising efficacy. It transiently arrests hematopoietic stem cells in the G1 phase, thus temporarily blocking progression…
Study Results: Subsequent Chemotherapy May Increase Risk of Joint Infection for Patients with Joint Replacements
Researchers at Sinai Hospital of Baltimore have found a possible relationship between receiving chemotherapy within a year of total joint replacement surgery and increased incidence of infection in the replaced joint. Findings published this month in the Archives of Orthopaedic and Trauma Surgery.
Donepezil Does Not Improve Chemotherapy-Related Cognitive Impairment
Researchers at Wake Forest University School of Medicine conducted a Phase III randomized, placebo-controlled trial to test donepezil, a cognitive-enhancing medicine used in the treatment of Alzheimer’s disease. The research team found that donepezil did not improve memory or other cognitive functions in survivors with cancer-related cognitive impairment.
New gene signature could transform immunotherapy for gastrointestinal cancers
A recent study in gastrointestinal (GI) cancer research reveals a promising advancement in predicting patient responses to immune checkpoint inhibitor (ICI) therapy. The newly developed DNA damage response-related immune activation (DRIA) signature could serve as a groundbreaking biomarker, providing valuable guidance for ICI therapy decisions.
Timing of Both Fasting and Meals Affects Degree of DNA Damage to Small Intestine Caused by Chemotherapy
Article title: Mechanisms driving fasting-induced protection from genotoxic injury in the small intestine Authors: Kali Deans-Fielder, Timothy Wu, Thanh Nguyen, Sarah To, Yang-Zhe Huang, Steven J. Bark, Jason C. Mills, Noah F. Shroyer From the authors: “Our results also showed…
MD Anderson Research Highlights for April 12, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Chemotherapy in Pediatric Mice Linked to Long-term Muscle Defects
Rockville, Md. (April 3, 2024)—Recent progress in research related to cancer treatment has made it possible for children with cancer to survive into adulthood. However, the long-term physiological consequences of chemotherapy are understudied. This study investigated persistent musculoskeletal consequences of…
Yale Cancer Center Experts, Scientists to Share Vision and Research at Leading Conference
The five-day session (April 5-10), themed as “Inspiring Science. Fueling Progress. Revolutionizing Care,” will include new findings from Yale Cancer Center researchers.
Answers from an Expert: Esophageal Cancer
Benjamin Medina, MD, thoracic surgeon in the Lung/Thoracic Oncology Program at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, answers common questions about esophageal cancer during esophageal cancer awareness month.
Medical and Psycho-Oncologists Available for Interviews
If you are seeking an expert to discuss chemotherapy and coping with potential side effects following a cancer diagnosis, Dr. Mikkael Sekeres is available. We also have available psycho-oncologists who can discuss the psychosocial aspects of dealing with the shock…
New treatment for a rare and aggressive cancer improves survival rates in breakthrough clinical trial
An innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options, according to results from a clinical trial led by Queen Mary University of London.
Researchers Discover Why One Type of Chemotherapy Works Best in Bladder Cancer
Tisch Cancer Institute researchers discovered that a certain type of chemotherapy improves the immune system’s ability to fight off bladder cancer, particularly when combined with immunotherapy, according to a study published in Cell Reports Medicine in January.
Johns Hopkins Medicine Researchers Create Machine Learning Model To Calculate Chemotherapy Success In Patients With Osteosarcoma
A research team at Johns Hopkins Medicine has created and trained a machine learning model to calculate percent necrosis (PN) — or, what percentage of a tumor is “dead” and no longer active — in patients with osteosarcoma, a type of bone cancer. The model’s calculation was 85% correct when compared to the results of a musculoskeletal pathologist.
Better use of existing drugs increases cervical cancer survival and reduces recurrence
A course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer, in trial results presented by researchers from UCL and UCLH.
MD Anderson Research Highlights: ESMO 2023 Special Edition
This special edition features upcoming oral presentations by MD Anderson researchers at the 2023 European Society for Medical Oncology (ESMO) Congress focused on clinical advances across a variety of cancer types.
RUDN Biochemists Found How to Weaken Cancer Cells
Biochemists from RUDN University described how to prevent cancer cells from becoming resistant to chemotherapy drugs. Having determined the resistance mechanism, biochemists selected a drug that can slow down it.
Breast Cancer at 30?
Amanda Butler and Isabella Bugatti, both just entering their 30s, were blindsided by a diagnosis that is on the rise among women their age: breast cancer.
MD Anderson Research Highlights for October 4, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson include a computer game that helps breast cancer survivors improve symptoms of peripheral neuropathy, a publicly available single-cell atlas of CD19 chimeric antigen receptor (CAR) T cells, new targets for TP53-mutant acute myeloid leukemia (AML), a preclinical target for preventing chemobrain, a blood test to help identify patients at higher risk of developing pancreatic cancer, and genomic insights to predict the risk of outcomes in patients with bone cancer.
Advanced Bladder Cancer Patients Could Keep Their Bladder Under New Treatment Regime, Clinical Trial Shows
Mount Sinai investigators have developed a new approach for treating invasive bladder cancer without the need for surgical removal of the bladder, according to a study published in Nature Medicine in September.
Researchers pioneer safe chemotherapy methods for treating bacterial infections
Antibiotic resistant bacteria are a threat to human lives, and yet the development of new drugs to treat bacterial infections is slow.
St. Jude shows cancer resistance protein can have its cake and eat it too
Scientists at St. Jude Research Hospital unravel the mechanisms behind a key culprit in chemotherapy resistance.
Research sheds new light on gene therapy for blood disorders
A study shows new steps toward more patients getting gene therapy
Study Offers Guidance for Improving Access to Oncology Drug Treatments in Sub-Saharan Africa
Botswana-Rutgers Partnership for Health researchers review treatments that could improve outcomes for patients in a region where cancer rates are rising significantly.
MD Anderson Research Highlights for June 7, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
MD Anderson Research Highlights for May 24, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
Palouse Specialty Oncology & Hematology Selects CureMD Oncology as Their EMR/PM Provider to Provide Best-in-Class Cancer Care Services in the Region
CureMD Oncology, a leading provider of all-inclusive technology solutions for community oncology, is delighted to announce its partnership with Palouse Specialty Physicians, a comprehensive cancer care provider in the Pacific Northwest region.
Chemotherapy Drug Increases Kidney Injury in Mouse Model of Lung Cancer
Article title: Lung cancer-kidney cross talk induces kidney injury, interstitial fibrosis, and enhances cisplatin-induced nephrotoxicity Authors: Andrew Orwick, Sophia M. Sears, Cierra N. Sharp, Mark A. Doll, Parag P. Shah, Levi J. Beverly, Leah J. Siskind From the authors: “This…
Anticancer drugs with fewer side-effects: scientists decode the crystal structure of a key cell cycle protein
Anticancer drugs are pivotal to cancer treatment, but their toxicity may not always be limited to cancer cells, resulting in harmful side-effects.
MD Anderson Research Highlights for March 29, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
Dual immunotherapy plus chemotherapy before surgery improves patient outcomes in operable lung cancer
In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).
Ochsner Health Advances Precision Medicine, Becomes National Leader in Universal Genomic Testing for Chemotherapy
Ochsner Health is leading the way for precision medicine nationwide by becoming one of the first hospital systems to standardize genomic testing, significantly advancing ways in which care teams can treat cancer patients. This change helps providers determine individualized treatment by understanding how patients will react to certain drugs, thereby lowering risk of adverse side effects, improving patient experience, and bettering patient outcomes.
MD Anderson Research Highlights for March 8, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Stress-Tolerant Cells Drive Tumor Initiation in Pancreatic Cancer
UC San Diego scientists discover a molecular pathway critical to the initiation of pancreatic tumors. The findings may inspire new chemotherapeutic drugs targeting early stages of tumor formation and spread.
Mouse study suggests new therapeutic strategy to reduce cardiovascular disease in cancer survivors
Researchers at Memorial Sloan Kettering Cancer Center (MSKCC) in New York have discovered that common cancer treatments, such as radiotherapy or anthracycline drugs, cause long-term damage to heart tissue by activating a key inflammatory signaling pathway. The study, published December 19 in the Journal of Experimental Medicine (JEM), suggests that inhibiting this pathway could reduce the chances of cancer survivors suffering heart disease later in life.
Immune system reboot in MS patients
Every day, one person in Switzerland is diagnosed with multiple sclerosis. MS is an autoimmune disease in which the body’s own immune system attacks the myelin sheath of the nerve cells in the brain and spinal cord.
New treatment can significantly increase the efficacy of chemotherapy and prevent metastasis
The researchers identified a mechanism that generated a cancer-promoting inflammatory environment in response to chemotherapy. Based on this discovery, they developed a treatment combination that reduced the incidence of lung metastasis following chemotherapy from 52% to only 6%.
Anti-sedative could alleviate cancer therapy side effects, study suggests
Researchers in China have discovered that inhibiting a protein called the GABAA receptor can protect intestinal stem cells from the toxic effects of chemotherapy and radiotherapy. The study, published September 20 in the Journal of Experimental Medicine (JEM), suggests that the FDA-approved anti-sedative flumazenil, which targets GABAA receptors, could alleviate some of the common gastrointestinal side effects, such as diarrhea and vomiting, induced by many cancer treatments.
A Survivor’s Guide to Brain Cancer
Sheri Saenz is enjoying everyday pleasures as a Laguna Niguel grandmother, crafting and camping with her granddaughter and grandson and vacationing with her husband of 34 years.
Neurofeedback shows promise for addressing ‘chemo brain’ in UCLA pilot study
The pilot study is one of the first to indicate that neurofeedback could help address cognitive deficits of cancer patients experiencing “chemo brain.”
A New Kind of Chemo
Researchers identify a new class of drugs that offer a safer, more targeted treatment for leukemia patients.
Groundbreaking research hopes to personalise treatment for cancer patients
Cancer Council SA-funded researcher Associate Professor Stephanie Reuter Lange from UniSA hopes that a simple computer program can help personalise treatment for cancer patients.
New Way to Protect White Blood Cells in Chemotherapy
A biochemist from RUDN and IBMC has found a way to protect healthy leukocytes during leukemia chemotherapy. Small nitrogen-containing polyamine molecules give the necessary protection. They are synthesized by almost all living cells, but only in normal lymphocytes, they exhibit protective properties.